BNGO - Bionano presents user experiences of Saphyr system

Announcing the results and experiences of six users of using its Saphyr® system for optical genome mapping (“OGM”) Bionano Genomics (BNGO) said that the research use only platform has demonstrated 100% concordance with standard methods.Featured in day one of Bionano’s five-day Next-Generation Cytogenomics Symposium, the presentations by scientists and clinicians from leading hospitals and medical research institutions in Europe, the US and China discussed the results from prenatal testing, infertility, and constitutional genetic disorders.Ravindra Kolhe, MD, Ph.D., Vice-Chairman of Pathology at the Medical College of Georgia at Augusta University, reported that Saphyr data yielded far more clinically relevant insights than traditional methods. He is developing a laboratory-developed test (“LDT”) for prenatal testing with Saphyr as a confirmatory diagnostic test for positive NIPT (noninvasive prenatal) tests.Yesterday, Bionano shares jumped in premarket after the company announced the first publication from the COVID-19 Host Genome Structural Variant Consortium. The consortium was formed by Dr. Ravindra Kolhe

For further details see:

Bionano presents user experiences of Saphyr system